Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment.
Dyslipidaemia including decreased high density lipoprotein cholesterol concentration is one of several factors that have been implicated in increased cardiovascular risk. Since their introduction in the 1980s, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have emerged as the one of the best-selling class of medications to date, with numerous trials demonstrating powerful efficacy in preventing cardiovascular diseases. Although statins have been shown to modestly raise or not alter HDL-cholesterol, their effect on HDL subfractions and on HDL-associated enzymes including human paraoxonase-1 (PON1) has not yet been fully explored. This review summarizes the currently available data on the effect of statins on HDL subfractions and on PON1 activity with a particular emphasis on the clinical relevance of these effects. Moreover, methodological problems of HDL subfraction and PON1 activity determinations are also discussed.
First Department of Medicine, Medical and Health Sciences Center, University of Debrecen, Nagyerdei krt. 98, 4032, Debrecen, Hungary.
Mariann
M
Harangi
Ildikó
I
Seres
János
J
Harangi
György
G
Paragh
D043303:Aryldialkylphosphatase / Q000097:blood* / Q000235:genetics; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D008075:Lipoproteins, HDL / Q000097:blood*; D011110:Polymorphism, Genetic
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008075:Lipoproteins, HDL; D043303:Aryldialkylphosphatase